Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Anticancer Res. 2020 Mar;40(3):1683-1690. doi: 10.21873/anticanres.14120.
This study aimed to investigate the impact of postoperative complications (PCs) in patients with pathological stage (pStage) II or III gastric cancer (GC) who received adjuvant chemotherapy with S-1 after curative surgery.
Altogether, data for 226 patients were examined retrospectively. The relationship between PCs and clinicopathological features and survival were examined.
Recurrence-free survival was significantly worse in the group with PCs than in the PC-negative group. On multivariate analysis, having PCs of grade 2 or more was an independent risk factor for recurrence (hazard ratio=1.721; 95% confidence intervaI=1.014-2.920; p=0.044). In addition, for each pStage analysis, having PCs of grade 2 or more was a risk factor for recurrence even in patients with pStage II GC.
PC of grade 2 or more was an independent risk factor for recurrence in patients with pStage II GC who received adjuvant chemotherapy with S-1 after curative gastrectomy. Thus, for patients with PCs, even for those with pStage II GC, more effective adjuvant chemotherapy, such as S-1 plus docetaxel, may be needed.
本研究旨在探讨接受根治性手术后辅助 S-1 化疗的病理分期（pStage）II 或 III 期胃癌（GC）患者术后并发症（PCs）对生存的影响。
回顾性分析了 226 例患者的数据。研究了 PCs 与临床病理特征和生存之间的关系。
PC 组的无复发生存明显差于 PC 阴性组。多因素分析显示，2 级及以上 PCs 是复发的独立危险因素（危险比=1.721；95%置信区间 1.014-2.920；p=0.044）。此外，对于每个 pStage 分析，即使在 pStage II GC 患者中，2 级及以上 PCs 也是复发的危险因素。
对于接受根治性胃切除术后辅助 S-1 化疗的 pStage II GC 患者，2 级及以上 PCs 是复发的独立危险因素。因此，对于有 PCs 的患者，即使是 pStage II GC 患者，也可能需要更有效的辅助化疗，如 S-1 联合多西紫杉醇。
